Kinney Horn - Dec 10, 2021 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role: CHIEF BUSINESS OFFICER
Signature: /s/ John B. Moriarty, Jr., Attorney-in-Fact
Stock symbol: OLMA
Transactions as of: Dec 10, 2021
Transactions value $: -$43,720
Form type: 4
Date filed: 12/14/2021, 03:25 PM
Previous filing: Nov 12, 2021
Next filing: Jan 11, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OLMA	Common Stock	Options Exercise	$10.8K	+5.25K	+213.63%	$2.06^*	7.71K	Dec 10, 2021	Direct	F1
transaction	OLMA	Common Stock	Sale	-$54.6K	-5.25K	-68.12%	$10.39	2.46K	Dec 10, 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OLMA	Stock Option (Right to Buy)	Options Exercise	$0	-5.25K	-3.23%	$0.00	158K	Dec 10, 2021	Common Stock	5.25K	$2.06	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 668 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2021.
F2	The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
F3	The weighted average sale price for the transaction reported was $10.39, and the range of prices were between $10.18 and $11.11. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F4	The shares subject to the option vest in a series of 48 successive equal monthly installments measured from June 10, 2020, subject to the Reporting Person's continuous service through each applicable vesting date.